Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial

A Ayal A. Aizer (Ayal A. Aizer, MD, MHS, Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA; Paul J. Catalano, ScD, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA; and Rifaquat Rahman, MD, Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA) S Shyam K. Tanguturi (Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA) D Diana D. Shi (Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.) P Paul J. Catalano K Kee-Young Shin (Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA) I Ivy Ricca (Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA) M Marciana Johnson (Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA) G Grant Benham (Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA) D David E. Kozono R Raymond H. Mak L Lauren Hertan (Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA) F Fallon Chipidza (Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA) M Monica Krishnan (Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA) I Itai Pashtan L Luke Peng (26Northeastern University, Boston, United States) J Jack M. Qian R Ron Y. Shiloh (Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA) D Daniel N. Cagney (Department of Radiation Oncology, Mater Private Hospital, Dublin, Ireland) J Jacob Sands (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA) P Paul D. Brown P Patrick Y. Wen D Daphne A. Haas-Kogan R Rifaquat Rahman (Brigham and Women's Hospital, Boston, MA)

Abstract

PURPOSE Stereotactic radiation (SRS/SRT) as opposed to whole-brain radiation (WBRT) represents the standard of care for patients with a limited number of brain metastases given the relatively favorable toxicity profile associated with stereotactic treatment. However, in patients with small cell lung cancer (SCLC), WBRT remains standard because of a lack of prospective data supporting SRS/SRT and concerns related to intracranial progression and neurologic death when WBRT is omitted. We conducted a single-arm, multicenter, phase II trial of SRS/SRT in patients with SCLC and 1-10 brain metastases to assess neurologic death rates relative to historical controls managed with WBRT (ClinicalTrials.gov identifier: NCT03391362 ). METHODS Patients were eligible if they had SCLC or an extrathoracic small cell primary and 1-10 brain metastases. Previous brain-directed radiation including prophylactic cranial irradiation was not permitted. Neurologic death was defined as marked, progressive, radiographic brain progression accompanied by corresponding neurologic symptomatology without systemic disease progression or systemic symptoms of a life-threatening nature. Close imaging-based surveillance of the brain post-SRS/SRT was used. RESULTS Between February 2018 and April 2023, 100 patients were enrolled. The median number of brain metastases was 2 (IQR, 1-4; range, 1-10). The median overall survival was 10.2 months; only 22% of patients required salvage WBRT. In total, 20 neurologic deaths were observed, relative to 64 non-neurologic deaths. The neurologic death rate at 1 year was 11.0% (95% CI, 5.8 to 18.1); the historical rate in patients managed with WBRT was 17.5%. CONCLUSION Our prospective, multi-institutional study demonstrated low rates of neurologic death when SRS/SRT as opposed to WBRT is used in patients with SCLC and 1-10 brain metastases who are surveilled closely post-treatment, supporting the utility of stereotactic approaches in this population.

Article Details

Volume / Issue Vol. 43, Issue 27
Published September 20, 2025
Pages 2986-2997
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (23)

A

Ayal A. Aizer

Ayal A. Aizer, MD, MHS, Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA; Paul J. Catalano, ScD, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA; and Rifaquat Rahman, MD, Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA

S

Shyam K. Tanguturi

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA

D

Diana D. Shi

Children’s Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.

P

Paul J. Catalano

K

Kee-Young Shin

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

I

Ivy Ricca

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA

M

Marciana Johnson

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA

G

Grant Benham

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA

D

David E. Kozono

R

Raymond H. Mak

L

Lauren Hertan

Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA

F

Fallon Chipidza

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA

M

Monica Krishnan

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA

I

Itai Pashtan

L

Luke Peng

26Northeastern University, Boston, United States

J

Jack M. Qian

R

Ron Y. Shiloh

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA

D

Daniel N. Cagney

Department of Radiation Oncology, Mater Private Hospital, Dublin, Ireland

J

Jacob Sands

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

P

Paul D. Brown

P

Patrick Y. Wen

D

Daphne A. Haas-Kogan

R

Rifaquat Rahman

Brigham and Women's Hospital, Boston, MA